WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)

Background: Fibroblast growth factor receptor 2b (FGFR2)-overexpressing advanced gastric cancer (AGC) is associated with poor prognosis and limited treatment options. Bemarituzumab, which selectively binds to FGFR2b, is being investigated in combination with chemotherapy as a first-line treatment. D...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	K. Shimozaki, K. Hirata, H. Hayashi, Y. Sato, Y. Komatsu, S. Taniguchi, N. Takahashi, K. Yamaguchi, M. Furuta, T. Kawakami, Y. Narita, T. Ando, A. Makiyama, S. Mitani, T. Ogata, N. Takegawa, W. Okamoto, T. Nishina, M. Komoda, A. Hosokawa, N. Boku, H. Kawakami, K. Yamazaki, K. Muro
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2025-09-01
Seri Bilgileri:	ESMO Gastrointestinal Oncology
Konular:	FGFR2b gastric cancer bemarituzumab
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2949819825000585
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!